CBD review sharpens the evidence picture for dogs and cats

A new mini-review in the Journal of Small Animal Practice offers an updated snapshot of where cannabidiol stands in small animal medicine: promising in some narrow use cases, still unsettled in many others. Author T. Sano summarizes the current clinical evidence for CBD in dogs and cats and concludes that the most credible support remains in canine osteoarthritis and refractory epilepsy, while evidence for anxiety-related disorders and for cats overall is much more limited. (pubmed.ncbi.nlm.nih.gov)

That conclusion fits the arc of the field over the past several years. CBD moved quickly from consumer trend to frequent exam-room question, often driven by pet parent demand for pain, seizure, itch, or behavior support. But the research base has lagged behind the market. Earlier systematic reviews found some support for pain reduction and improved activity in dogs with osteoarthritis, but much weaker evidence for epilepsy and behavioral indications, largely because studies were small and methods varied widely. More recent reviews suggest the signal for canine benefit is getting stronger, but they still describe the literature as limited, heterogeneous, and far less developed in cats. (pubmed.ncbi.nlm.nih.gov)

The practical takeaway is less about a breakthrough and more about refinement. In osteoarthritis, multiple veterinary studies and reviews now point to moderate improvements in pain or mobility in some dogs, supporting CBD's role as a possible adjunct rather than a replacement for established multimodal care. In epilepsy, Colorado State University investigators previously reported encouraging results in dogs with idiopathic epilepsy, including reduced seizure frequency in a small trial, and CSU continues to list active CBD-related epilepsy studies. By contrast, evidence for anxiety, aggression, and other behavioral uses remains preliminary, and feline clinical data remain sparse. (aaha.org)

Safety and product consistency remain central concerns. Reviews and professional summaries have repeatedly pointed to variable formulations, uncertain labeling accuracy, and the need to monitor for adverse effects, including liver enzyme elevations reported in some dogs. Those issues matter because most products used in practice are not standardized like approved pharmaceuticals, making it harder to compare dose, bioavailability, and outcomes across studies or between patients. (aaha.org)

Industry and expert commentary has been broadly consistent: there's real veterinary interest, and likely some clinical utility, but not enough high-quality evidence to justify casual recommendations. AAHA coverage has described the osteoarthritis data in dogs as moderately encouraging and highlighted a seizure study showing about a one-third reduction in frequency and severity in some dogs, while also noting that the clinical relevance of lab changes such as ALP elevations is still being worked out. Other veterinary experts, including toxicology voices and academic commentators, have framed CBD as a potentially useful adjunct that requires much better education, product selection, and client counseling than the current marketplace usually provides. (aaha.org)

Why it matters: For veterinarians, this review helps sharpen the boundary between evidence-informed use and market-driven use. If a clinic is discussing CBD at all, the most defensible conversations are still around adjunctive therapy for canine osteoarthritis or refractory epilepsy, not broad claims across pain, anxiety, dermatology, or feline medicine. It also underscores the need to document product selection, discuss uncertain efficacy, review potential drug interactions, and monitor patients rather than treating CBD as a benign supplement. (pubmed.ncbi.nlm.nih.gov)

The regulatory backdrop makes that discipline even more important. FDA says there are currently no approved, conditionally approved, or indexed animal drugs containing CBD, and no approved hemp-derived ingredients listed for animal food use. In early 2025, the agency formally sought more public input on veterinary use of cannabis-derived products, including quality standards, safety signals, interactions, and adverse events. Meanwhile, model guidance efforts such as the AAVSB's 2026 companion-animal CBD document suggest the profession is still trying to catch up to what pet parents are already asking for in practice. (fda.gov)

What to watch: The next phase will likely hinge on better-controlled trials, clearer product standards, and more explicit state-by-state guardrails for veterinary discussion and recommendation, especially as demand keeps outpacing both regulation and feline-specific evidence. (pubmed.ncbi.nlm.nih.gov)